Published • loading... • Updated
NIQ Announces Third Quarter 2026 Results
Summary by Joplin Globe
7 Articles
7 Articles
Ascendis Pharma Reports Third Quarter 2026 Financial Results
Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH®, €59 million for SKYTROFA®, and €16 million for YUVIWEL®Received positive CHMP and COMP opinions recommending EU marketing authorization and maintenance of orphan medicinal product designation for…
StablecoinX to Report Third Quarter 2026 Financial Results on Monday, November 16, and Host Business Update Webcast on Tuesday, November 17
NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- StablecoinX Inc. (Nasdaq: USDE), the first public stablecoin infrastructure company focusing on the Ethena digital dollar ecosystem,...
·Manila, Philippines (the)
Read Full ArticleCoverage Details
Total News Sources7
Leaning Left1Leaning Right2Center3Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 17%
C 50%
R 33%
Factuality
To view factuality data please Upgrade to Premium
